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Background: Mithramycin, chromomycin, and olivomycin belong to the aureolic 
acid family of clinically important anti-tumor agents. These natural products share 
a common aromatic aglycone. Although isotope labeling studies have firmly 
established the polyketide origin of this aglycone, they do not distinguish between 
alternative biosynthetic models in which the aglycone is derived from one, two or 
three distinct polyketide moieties. We set out to determine the biosynthetic origin 
of this moiety using a recombinant approach in which the ketosynthase and chain- 
length factor proteins from the antibiotic-producer strain, which determine the 
chain length of a polyketide, are produced in a heterologous bacterial host. 
Results: The ketosynthase and chain-length factor genes from the polyketide 
synthase gene cluster from the mithramycin producer, Streptomyces argillaceus 
ATCCI 2956, and the acyl carrier protein and ketoreductase genes from the 
actinorhodin polyketide synthase were expressed in Streptomyces coelicolor 
CHQQQ. The recombinant strain produced a 20-carbon polyketide, comprising 
the complete backbone of the aglycone of mithramycin. 
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Conclusions: The aglycone moieties of mithramycin, chromomycin, and 
olivomycin are derived from a single polyketide backbone. The nascent 
polyketide backbone must undergo a series of regiospecific cyclizations to form 
a tetracenomycin-like tetracyclic intermediate. The final steps in the aglycone 
biosynthetic pathway presumably involve decarboxylation and oxidative cleavage 
between C-l 8 and C-l 9, followed by additional oxidation, reduction, and 
methylation reactions. 
Introduction 
Mithramycin, chromomycin, and olivomycin (Fig. 1) 
comprise the aureolic acid group of anti-tumor agents 
[l-3]. Although their mode of action is not completely 
understood, it is well-known that they interact with GC- 
rich DNA regions in a non-intercalative manner, requiring 
Mg2+ ions for activity [4]. They also possess antibiotic 
activity against gram-positive, but not gram-negative, 
bacteria. Mithramycin is used clinically in the treatment of 
some tumor diseases [S]. 
The aglycones of these three natural products are very 
similar, and consist of a tricyclic chromophore (designated 
as mithramycinone in the case of mithramycin). A 
disaccharide (D-olivose and D-olivose in mithramycin) and 
a trisaccharide (D-olivose, D-olivose and L-mycarose in 
mithramycin) are attached to this chromophore at 
positions 6 and 2, respectively. Isotope labeling studies 
(Fig. 2) have established that the entire carbon skeleton of 
the chromomycin aglycone is derived from acetate [6,7], 
suggesting a polyketide biosynthetic mechanism [S]. The 
unusual labeling pattern observed in these studies in the 
aliphatic moiety of the aglycone, however, has precluded 
unambiguous determination of its biosynthetic pathway. 
Indeed, it has been argued that the aglycone could be 
derived from a condensation of two or even three 
independently synthesized polyketide intermediates 
[6,7]. But it is also possible that the characteristic structure 
of chromomycinone (and, by analogy, mithramycinone) 
could be derived from a tetracenomycin-like tetracyclic 
intermediate that undergoes cleavage of a C-C bond [9]. 
The mtm locus from Streptomyces argillaceus ATCCl29.56, 
the bacterium that produces mithramycin, has recently 
been cloned [lo]. Sequence analysis revealed a set of 
genes with a high degree of similarity to other bacterial 
aromatic polyketide synthases ([ 1 l-131; reviewed in [ 141). 
Chromosomal disruption at this locus resulted in ablation 
of mithramycin production in S. argillaeus, confirming the 
notion that this polyketide synthase is involved in the 
mithramycin biosynthetic pathway [lo]. 
Bacterial aromatic polyketide synthases are structurally 
and mechanistically related to each other and to the 
fatty acid synthases [8,14]. These multifunctional en- 
zymes catalyze repeated decarboxylative condensations 
194 Chemistry 6 Biology 1996, Vol3 No 3 
Fiaure 1 - .e--- - 
4 HoM*&coMe O
bH Mithramycin 
6H 6H I 
HOa0 
HOW 
HO 
Olivomycin A (RI = H, R2 = i-Pr) 
Chromomycin As (Rt = R2 = Me) 
Structures of mithramycin, chromomycin, and olivomycin. 
between acyl-CoA primers (usually acetyl-CoA) and 
malonyl-CoA extender units. After the carbon chain 
backbone has grown to its final chain length, it 
undergoes a series of regiospecific reduction, 
aromatization, and cyclization steps leading to the 
formation of a polycyclic aromatic polyketide. The chain 
length of the polyketide is exclusively controlled by two 
subunits of the minimal polyketide synthase, the 
ketosynthase and the chain-length factor [15-161. 
Analysis of the chain-length specificity of the mtm 
polyketide synthase should help to determine the 
number of distinct polyketide moieties (and 
consequently, the number of polyketide synthases) 
involved in mithramycin biosynthesis. Here we report on 
the specificity of the mtm polyketide synthase for the 
chain length of its product. To isolate the ketosynthase 
and chain-length factor genes of the mtm polyketide 
synthase from other synthases that might be present 
in this gene cluster, we expressed them in a hetero- 
logous host, from which the entire polyketide locus has 
been deleted. 
Results and discussion 
To deduce the chain-length specificity of the mtm 
polyketide synthase, a hybrid polyketide synthase gene 
cluster was cloned into plasmid pRM5 [ 151; recombinant 
polyketide synthase is produced from this vector at the 
onset of the stationary phase in Streptomyces coelicolor 
CH999 [IS], an appropriately engineered expression host. 
This hybrid gene cluster included the mtm ketosynthase 
and the mtm chain-length factor, as well as the acyl carrier 
protein and the ketoreductase from the actinorhodin (act) 
gene cluster. The polyketide products of the resulting 
recombinant strain, CH999/pGBl, were purified and 
structurally analyzed by ‘H and 13C NMR spectroscopy. 
The two most abundant products were found to be 
identical to two decaketides, RMZOb and RMZOc (Fig. 3), 
previously isolated from a recombinant strain, 
CH999/pRMZO, that expresses the tetracenomycin (tcm) 
ketosynthase and chain-length factor, together with the act 
acyl carrier protein and ketoreductase [17].Thus, the 
synthesis of these ‘hybrid’ polyketides once again 
illustrates the potential for combinatorial biosynthesis 
using protein components from different polyketide 
synthases. The product yields for RMZOb and RMZOc 
were similar from both recombinant strains (90 mg 1-l and 
12 mg l-l, respectively). The recently cloned mtm 
polyketide synthase gene cluster thus specifies production 
of a ZO-carbon polyketide chain. 
Of the various alternative models for the biosynthesis of 
the carbon skeleton of mithramycinone, the only one 
consistent with the above result is shown in Fig. 4. Here, 
the mtm minimal polyketide synthase (comprising 
ketosynthase, chain-length factor, and acyl carrier 
protein) uses an acetyl CoA primer unit and nine malonyl 
CoA extender units to form a decaketide backbone, 
which then undergoes four successive intramolecular 
cyclization and dehydration steps, leading to the 
formation of tetracenomycin Fl (compound 1) [18]. 
Decarboxylation yields compound 2, which then 
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The mithramycin aglycone is probably made by a polyketide 
synthase. The acetate incorporation pattern as deduced from 
isotope labeling experiments is shown; such patterns are diagnostic 
of compounds made by polyketide synthases 
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Figure 3 
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The aglycone of mithramycin is derived from a single polyketide 
backbone. Isomers RMPOb and RM20c of the reduced polyketide 
(right) are the primary products of S. coelicolor CH999 expressing 
mtm ketosynthase (KS), mtm chain-length factor (CLP), act acyl carrier 
protein (ACP) and act ketoreductase (KR). 
undergoes oxidative cleavage between Cl8 and C19, members of this interesting class of anti-tumor agents 
giving rise to compound 3. Subsequent oxidation, probably encode one and only one polyketide synthase. 
reduction, and methylation reactions result in Further genetic and chemical analysis of the mtm gene 
mithramycinone formation. The biosynthetic pathways cluster will shed light on the precise functions and 
leading to the formation of the aglycone moieties of mechanisms of the remarkable post-polyketide synthase 
chromomycin and olivomycin are presumably very enzymes involved in the biosynthesis of this structurally 
similar. Thus, the gene cluster for biosynthesis of interesting and medicinally important natural product. 
Figure 4 
0 
+ 9 
SCoA 
C02H 
OH OH 0 
Mithramycinone 
OMe OH 
Deduced biosynthetic pathway of mithramycinone, the mithramycin (compound 1) (181. Decarboxylation follows to yield compound 2, 
aglycone. The decaketide backbone synthesized by the mtm minimal which then undergoes oxidative cleavage between Cl 8 and Cl 9, 
PKS undergoes four successive intramolecular cyclization and giving rise to compound 3. Subsequent oxidation, reduction, and 
dehydration steps, leading to the formation of tetracenomycin Fl methylation reactions result in mithramycinone formation. 
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Significance 
We show here that a hybrid polyketide synthase, which 
includes the mithramycin ketosynthase and chain- 
length factor together with the acyl carrier protein and 
ketoreductase from the actinorhodin polyketide 
synthase, results in the biosynthesis of a 20-carbon 
polyketide that undergoes a C-9 ketoreduction. Thus, 
the aglycones of mithramycin, chromomycin, and 
olivomycin must be derived from a single polyketide 
backbone, instead of two or three. The nascent 
polyketide backbone must undergo a series of 
regiospecific cyclizations to form a tetracenomycin-like 
tetracyclic intermediate. The final steps in the aglycone 
biosynthetic pathway presumably involve 
decarboxylation and oxidative cleavage between C-18 
and C-19, followed by additional oxidation, reduction, 
and methylation reactions. 
Our results rule out the possible involvement of a 
second polyketide synthase in the biosynthesis of the 
aureolic acid family of natural products. They also 
emphasize the value of a versatile host-vector system 
for heterologous expression of recombinant natural 
product gene clusters. Finally, the synthesis of a ‘hybrid’ 
polyketide by subunits from the mithramycin and the 
actinorhodin polyketide synthases once again highlights 
the potential for combinatorial biosynthesis of 
‘unnatural’ natural products. 
Materials and methods 
Bacterial strains, plasmid construction, and culture conditions 
The mfm kefosynthase and chain-length factor genes were engineered 
by PCR amplification as a Pacl-Xbal cassette using the following 
primer sequences: (5’) TTTTAAGCTTAATTAAGGAGGACCATCAT- 
GAACCGFCGCGTCGTC; (3’) TTT-TGAAT-TCTAGATTAGGACAAG- 
GCCCGCACGA. Plasmid pGB1 was constructed by replacing the 
act ketosynthase and act chain-length factor genes in pRM5 [I 51 with 
the corresponding mtm genes engineered as above. 
Purification of polyketides from CH999IpGB 1 
S. coelicolor CHQQQ/pGBl was grown on RSYE agar medium 
(-500 ml) containing 50 mg I-’ thiostrepton at 30 “C for 6 days. The 
agar was chopped and extracted with 3 x500 ml ethyl 
acetate:methanol (5:l) containing 1 %  acetic acid. The solvent was 
removed under vacuum. The residue was applied to a Florisil column 
(Fisher Scientific) and eluted with ethyl acetate:ethanol:acetic acid 
(17:2:1). Eluted fractions were further purified on a Beckman HPLC 
using a preparative C-16 reverse-phase column (mobile phase, 
acetonitrile:water = 1 :Q to 3:2 over a period of 53 min). The yields of 
the two most abundant products thus purified, RMPOb and RM20c 
1171, were 45 mg and 6 mg, respectively. 
NM R spectroscopy 
13C and ‘H NMR spectra were recorded on a Varian XL-400 using 
DMSO-d, as solvent. Spectra were referenced internally to the solvent 
for 13C NMR and to TMS for tH NMR. 
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